title: Deleterious cognitive and motoric effects of haloperidol in an adolescent with cerebral palsy: a case report.
abstract: This case report describes a 15-year-old male patient with spastic diplegic cerebral palsy, Gross Motor Function Classification System Level III, who developed severe new cognitive and motoric impairments after the administration of haloperidol. He received this dopamine antagonist and typical antipsychotic medication for an acute postoperative episode of agitation. He improved when he received the dopamine agonists amantadine and carbidopa/levodopa. This case suggests that dopamine blockade may be deleterious for individuals with cerebral palsy. Potential explanations for the events observed in this case are also presented.
authors: Department of Physical Medicine and Rehabilitation, The Ohio State University Medical Center, 186 S. Front Street, Apt. 209, Columbus, OH 43214(∗). Electronic address: diane.mortimer67@gmail.com.
authors: Diane
authors: D
authors: Mortimer
authors: Division of Physical Medicine and Rehabilitation, Nationwide Children's Hospital; and Department of Physical Medicine and Rehabilitation, The Ohio State University Medical Center, Columbus, OH(‡).
authors: Carl D
authors: CD
authors: Gelfius
authors: Division of Physical Medicine and Rehabilitation, Nationwide Children's Hospital, Columbus OH; and Department of Physical Medicine and Rehabilitation, The Ohio State University Medical Center, Columbus, OH(†).
authors: Michelle A
authors: MA
authors: Potts
mesh_terms: D000293:Adolescent; D000547:Amantadine / Q000627:therapeutic use; D002230:Carbidopa / Q000627:therapeutic use; D002547:Cerebral Palsy / Q000188:drug therapy* / Q000523:psychology*; D003072:Cognition Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D018491:Dopamine Agonists / Q000627:therapeutic use; D018492:Dopamine Antagonists / Q000009:adverse effects*; D004338:Drug Combinations; D006220:Haloperidol / Q000009:adverse effects*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D011596:Psychomotor Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy
chemical_list: D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D004338:Drug Combinations; C009265:carbidopa, levodopa drug combination; D007980:Levodopa; D000547:Amantadine; D006220:Haloperidol; D002230:Carbidopa